Literature DB >> 21325411

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.

Xueling Wu1, Anita Changela, Sijy O'Dell, Stephen D Schmidt, Marie Pancera, Yongping Yang, Baoshan Zhang, Miroslaw K Gorny, Sanjay Phogat, James E Robinson, Leonidas Stamatatos, Susan Zolla-Pazner, Peter D Kwong, John R Mascola.   

Abstract

HIV-1 is neutralized by a class of antibodies that preferentially recognize a site formed on the assembled viral spike. Such quaternary structure-specific antibodies have diverse neutralization breadths, with antibodies PG16 and PG9 able to neutralize 70 to 80% of circulating HIV-1 isolates while antibody 2909 is specific for strain SF162. We show that alteration between a rare lysine and a common N-linked glycan at position 160 of HIV-1 gp120 is primarily responsible for toggling between 2909 and PG16/PG9 neutralization sensitivity. Quaternary structure-specific antibodies appear to target antigenic variants of the same epitope, with neutralization breadth determined by the prevalence of recognized variants among circulating isolates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325411      PMCID: PMC3126226          DOI: 10.1128/JVI.02585-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding.

Authors:  Stephanie M J Rainwater; Xueling Wu; Ruth Nduati; Rebecca Nedellec; Donald Mosier; Grace John-Stewart; Dorothy Mbori-Ngacha; Julie Overbaugh
Journal:  Curr HIV Res       Date:  2007-03       Impact factor: 1.581

Review 4.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

5.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Authors:  W J Honnen; C Krachmarov; S C Kayman; M K Gorny; S Zolla-Pazner; A Pinter
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.

Authors:  A J Conley; M K Gorny; J A Kessler; L J Boots; M Ossorio-Castro; S Koenig; D W Lineberger; E A Emini; C Williams; S Zolla-Pazner
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1.

Authors:  Catherine A Blish; Zahra Jalalian-Lechak; Stephanie Rainwater; Minh-An Nguyen; Ozge C Dogan; Julie Overbaugh
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

10.  Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Authors:  Tongqing Zhou; Ling Xu; Barna Dey; Ann J Hessell; Donald Van Ryk; Shi-Hua Xiang; Xinzhen Yang; Mei-Yun Zhang; Michael B Zwick; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Joseph Sodroski; Richard Wyatt; Gary J Nabel; Peter D Kwong
Journal:  Nature       Date:  2007-02-15       Impact factor: 49.962

View more
  34 in total

Review 1.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

2.  A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Ivelin Georgiev; Sijy O'Dell; Gwo-Yu Chuang; Ryan P Staupe; Jason S McLellan; Jason Gorman; Marie Pancera; Mattia Bonsignori; Barton F Haynes; Dennis R Burton; Wayne C Koff; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

4.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

5.  Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.

Authors:  Mattia Bonsignori; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Lynn Morris; Elin Gray; Dawn J Marshall; John A Crump; Saidi H Kapiga; Noel E Sam; Faruk Sinangil; Marie Pancera; Yang Yongping; Baoshan Zhang; Jiang Zhu; Peter D Kwong; Sijy O'Dell; John R Mascola; Lan Wu; Gary J Nabel; Sanjay Phogat; Michael S Seaman; John F Whitesides; M Anthony Moody; Garnett Kelsoe; Xinzhen Yang; Joseph Sodroski; George M Shaw; David C Montefiori; Thomas B Kepler; Georgia D Tomaras; S Munir Alam; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

6.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

7.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

8.  Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.

Authors:  Tongqing Zhou; Nicole A Doria-Rose; Cheng Cheng; Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Michael Chambers; Aliaksandr Druz; Hui Geng; Krisha McKee; Young Do Kwon; Sijy O'Dell; Mallika Sastry; Stephen D Schmidt; Kai Xu; Lei Chen; Rita E Chen; Mark K Louder; Marie Pancera; Timothy G Wanninger; Baoshan Zhang; Anqi Zheng; S Katie Farney; Kathryn E Foulds; Ivelin S Georgiev; M Gordon Joyce; Thomas Lemmin; Sandeep Narpala; Reda Rawi; Cinque Soto; John-Paul Todd; Chen-Hsiang Shen; Yaroslav Tsybovsky; Yongping Yang; Peng Zhao; Barton F Haynes; Leonidas Stamatatos; Michael Tiemeyer; Lance Wells; Diana G Scorpio; Lawrence Shapiro; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  Cell Rep       Date:  2017-04-25       Impact factor: 9.423

9.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

10.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.